» Articles » PMID: 35121809

Treatment Outcomes of Mycobacterium Avium Complex Pulmonary Disease According to Disease Severity

Overview
Journal Sci Rep
Specialty Science
Date 2022 Feb 5
PMID 35121809
Authors
Affiliations
Soon will be listed here.
Abstract

Mycobacterium avium complex pulmonary disease (MAC-PD) requires long-term treatment. We analyzed the outcomes of 992 MAC-PD patients according to disease severity and compared the outcomes of intermittent and daily therapy for mild disease. Patients were divided into groups according to severity using the body mass index, age, cavity, erythrocyte sedimentation rate, and sex (BACES) system, and culture conversion rates were evaluated. We also evaluated the effects of intermittent treatment on the culture conversion rates in mild disease group. Using the BACES, 992 patients were divided into mild (n = 331), moderate (n = 503), and severe (n = 158) disease groups, and culture conversion at the end of treatment was achieved in 85% (282/331), 80% (403/503), and 61% (97/158), respectively. Differences in culture conversion among the severity groups were significant (p < 0.001). In patients with mild disease, culture conversion rates were similar between intermittent (84%, 166/198) and daily (87%, 116/133) treatment (p = 0.396), and intermittent antibiotic therapy did not negatively impact culture conversion (adjusted hazard ratio 1.08; confidence interval 0.83-1.41; p = 0.578). MAC-PD patients with mild disease had higher culture conversion rates. Daily and intermittent therapy yielded similar culture conversion rates for mild disease. Treatment strategies with lower pill burden may be applicable in mild MAC-PD.

Citing Articles

Inhibitors of acetohydroxyacid synthase as promising agents against non-tuberculous mycobacterial diseases.

Nguyen T, Choi J, Lim H, Chae C, Lee J, Son S J Antibiot (Tokyo). 2024; 78(3):181-189.

PMID: 39672903 DOI: 10.1038/s41429-024-00799-z.


The Clinical Implications of Serum Carbohydrate Antigen 19-9 Levels in Patients with Nontuberculous Mycobacteria Pulmonary Disease.

Lee D, Jhun B J Clin Med. 2023; 12(24).

PMID: 38137819 PMC: 10743919. DOI: 10.3390/jcm12247751.


Spontaneous Cultural Conversion Rate of Complex Pulmonary Disease Based on BACES Severity.

Kim B, Yu J, Jhun B J Clin Med. 2023; 12(22).

PMID: 38002737 PMC: 10671925. DOI: 10.3390/jcm12227125.


Treatment outcomes and relapse in patients with complex pulmonary disease.

Chang C, Yu C, Hsueh P, Chien J Microbiol Spectr. 2023; :e0164023.

PMID: 37754771 PMC: 10581154. DOI: 10.1128/spectrum.01640-23.

References
1.
Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P . The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013; 42(6):1604-13. DOI: 10.1183/09031936.00149212. View

2.
Kim H, Kwak N, Hong H, Kang N, Im Y, Jhun B . BACES Score for Predicting Mortality in Nontuberculous Mycobacterial Pulmonary Disease. Am J Respir Crit Care Med. 2020; 203(2):230-236. DOI: 10.1164/rccm.202004-1418OC. View

3.
Moon S, Yoo I, Huh H, Lee N, Jhun B . Intermittent Treatment with Azithromycin and Ethambutol for Noncavitary Mycobacterium avium Complex Pulmonary Disease. Antimicrob Agents Chemother. 2019; 64(1). PMC: 7187621. DOI: 10.1128/AAC.01787-19. View

4.
Griffith D, Aksamit T, Brown-Elliott B, Catanzaro A, Daley C, Gordin F . An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175(4):367-416. DOI: 10.1164/rccm.200604-571ST. View

5.
Daley C, Iaccarino J, Lange C, Cambau E, Wallace Jr R, Andrejak C . Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J. 2020; 56(1). PMC: 8375621. DOI: 10.1183/13993003.00535-2020. View